Form 4: BioCardia CEO Peter Altman Acquires Shares and Warrants in Public Offering

BioCardia's CEO, Peter Altman, acquired 41,666 shares of common stock and warrants in a recent public offering.

Summary

• On September 3, 2024, Peter Altman, the President and CEO of BioCardia, Inc., acquired 41,666 shares of common stock at a price of $3 per share.
• Altman also received 41,666 warrants to purchase shares of common stock, with an exercise price of $3, expiring on September 3, 2029.
• These shares and warrants were obtained through a public offering where one share of common stock and one warrant were received for each share purchased.
• Following the transaction, Altman directly owns 81,411 shares of BioCardia common stock and 41,666 warrants.

Sentiment

Score: 7

Explanation: The CEO's purchase of shares and warrants signals confidence in the company, which is generally a positive sign. However, it's a routine filing related to a previously announced public offering.

Positives

• The CEO's participation in the public offering demonstrates confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by the CEO is generally viewed positively.

Stakeholder Impact

• The CEO's purchase could positively influence investor sentiment.

Key Dates

Keywords

BioCardia, BCDA, Peter Altman, insider trading, Form 4, public offering, warrants, common stock, acquisition